The DOI matches its Crossref record; 58 of the 60 references it cites were found in a registry or an index.
Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation
Open accessAbstract
Previous studies have shown that the translation level of in vitro transcribed messenger RNA (mRNA) is enhanced when its uridines are replaced with pseudouridines; however, the reason for this enhancement has not been identified. Here, we demonstrate that in vitro transcripts containing uridine activate RNA-dependent protein kinase (PKR), which then phosphorylates translation initiation factor 2-alpha (eIF-2α), and inhibits translation. In contrast, in vitro transcribed mRNAs containing pseudouridine activate PKR to a lesser degree, and translation of pseudouridine-containing mRNAs is not repressed. RNA pull-down assays demonstrate that mRNA containing uridine is bound by PKR more efficiently than mRNA with pseudouridine. Finally, the role of PKR is validated by showing that pseudouridine- and uridine-containing RNAs were translated equally in PKR knockout cells. These results indicate that the enhanced translation of mRNAs containing pseudouridine, compared to those containing uridine, is mediated by decreased activation of PKR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Substitution of chemically modified nucleotides in messenger ribonucleic acid (mRNA) enhances stability and transfection capability, and decreases immunogenicity1–3”
From Complete substitution with modified nucleotides in self-amplifying RNA suppresses the interferon response and increases potency (2025) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Native RNA activates pattern recognition receptors such as toll-like receptors and triggers type I interferon (IFN) production, resulting in translational shutoff and systemic inflammation3.”
From Complete substitution with modified nucleotides in self-amplifying RNA suppresses the interferon response and increases potency (2025) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This can be circumvented by the incorporation of naturally occurring nucleosides and by applying stringent purification to remove double-stranded RNA contaminants (19–21).”
From mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model (2022) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Transferring this concept to in vitro transcribed mRNA, for instance, pseudouridine-containing mRNAs reduced activation of known RNA sensors substantially.”
From Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals (2015) · cites this paper as [22]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The two uridine analogs pseudouridine (Ψ) or 1-methyl-pseudouridine (m1Ψ) are widely used for mRNA therapeutics because they can increase mRNA stability and help modulate the host immune response31,32.”
From Human 5′ UTR design and variant effect prediction from a massively parallel translation assay (2019) · cites this paper as [32]
Experimental — accuracy not yet measured
The cited source says what the claim attributes to it.
In the citing paper
“Although pseudouridine is primarily found in tRNA, rRNA, and small nuclear RNAs, pseudouridine-containing mRNAs were still translated and produced even more protein compared to unmodified mRNA.”
From Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals (2015) · cites this paper as [22]
The cited source says what the claim attributes to it.
In the citing paper
“In addition, nucleoside modifications are well known to limit or even inhibit RNA sensor engagement.20,21,22”
From Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals (2015) · cites this paper as [22]
In the citing paper
“Nucleoside-modified mRNA can reduce the activation of TLRs, retinoic acid-inducible gene I (RIG-I), protein kinase R (PKR), and 2′-5′-oligoadenylate synthetase (OAS). Additionally, nucleoside modification increases translation activity and resistance against RNase L-mediated degradation.54,81,173–176”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [174]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728
Self-citation5'-Triphosphate RNA Is the Ligand for RIG-I
Hornung, V., Ellegast, J., Kim, S., Brzózka, K., Jung, A., Kato, H., Poeck, H., Akira, S., Conzelmann, K.-K., Schlee, M., et al. (2006) · Science · doi:10.1126/science.1132505 · Cited by 2,474
Karikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Self-citationActivation of the interferon system by short-interfering RNAs
Sledz, C. A., Holko, M., de Veer, M. J., Silverman, R. H., & Williams, B. R. G. (2003) · Nature Cell Biology · doi:10.1038/ncb1038 · Cited by 1,401
AAV vector integration sites in mouse hepatocellular carcinoma
Donsante, A., Miller, D. G., Li, Y., Vogler, C., Brunt, E. M., Russell, D. W., & Sands, M. S. (2007) · Science · doi:10.1126/science.1142658 · Cited by 662
Pseudouridine in RNA: What, Where, How, and Why
Charette, M., & Gray, M. W. (2000) · IUBMB Life · doi:10.1080/152165400410182 · Cited by 600
Ryter, J. M., & Schultz, S. C. (1998) · The EMBO Journal · doi:10.1093/emboj/17.24.7505 · Cited by 479
The RNA Modification Database: 1999 update
Rozenski, J., Crain, P. F., & McCloskey, J. A. (1999) · Nucleic Acids Research · doi:10.1093/nar/27.1.196 · Cited by 390
2′-O-methyl-modified RNAs Act as TLR7 Antagonists
Robbins, M., Judge, A. D., Liang, L. Y., McClintock, K., Yaworski, E., & MacLachlan, I. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300240 · Cited by 339
Genotoxicity of Retroviral Integration In Hematopoietic Cells
Nienhuis, A. W., Dunbar, C. E., & Sorrentino, B. P. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.03.001 · Cited by 301
Flagged first, then by citations
2 of the 60 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 601–684 of 684
5‐Ethynyluridine: A Bio‐orthogonal Uridine Variant for mRNA‐Based Therapies and Vaccines
Maassen, S., Coenen, B. A., Dülk, S.-L., van der Werff, M., Warner, H. M., Spada, F., Frischmuth, T., Incarnato, D., & van den Bogaart, G. (2023) · ChemBioChem · doi:10.1002/cbic.202200658
Vaccine Design Strategies: Pathogens to Genomes
McMullan, N. (2021) · Royal Society of Chemistry eBooks · doi:10.1039/9781788017862-00440
Metabolic engineering Escherichia coli for high-level production of pseudouridinePreprint
Zhou, M., Tang, R., Wei, L., Wang, J., & Qi, H. (2023) · Research Square · doi:10.21203/rs.3.rs-3007742/v1
Wu, X., Liang, C., Lei, Y., Xu, P., Zhang, Y., Yang, G., Yin, H., & Xu, K. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.07.22.550185
mRNA vaccine encoding neoantigen for cancer immunotherapy using mouse melanoma as a model
Sittplangkoon, C., & Palaga, T. (2021) · Chula Digiverse · doi:10.58837/chula.the.2021.23
Nucleic acid delivery by cell-penetrating peptides
Langel, Ü. (2023) · Proceedings of the Estonian Academy of Sciences · doi:10.3176/proc.2023.4.01 · Cited by 1
Incorporation of Pseudouridine into RNA for Biochemical and Biophysical Studies
Sanford, T. C., Riley, A., Clawson, M., Raasch, K., Oyebamiji, R., & Sumita, M. (2023) · RNA technologies · doi:10.1007/978-3-031-36390-0_25
YuanChao, X. U. E. (2023) · Scientia Sinica Vitae · doi:10.1360/ssv-2023-0236
The pivotal role of uridine modifications in the development of mRNA technology
Rzymski, P. (2023) · Journal of Medical Science · doi:10.20883/medical.e938
How much genuine is mRNA vaccine: Transferring message of small size grabbed Nobel Prize
Goswami, T. K. (2023) · Indian Journal of Animal Health · doi:10.36062/ijah.2023.15223
Комісаренко, С. В., & Романюк, С. И. (2023) · Visnik Nacional noi academii nauk Ukrai ni · doi:10.15407/visn2023.12.003
Nagroda Nobla 2023 za wkład w opracowanie szczepionek typu mRNA przeciw COVID-19
Płytycz, B. (2024) · Kosmos · doi:10.36921/kos.2023_2968
Erratum to: Progress Note 2024: Curing HIV; Not in My Lifetime or Just Around the Corner?
Harper, J., Betts, M. R., Lichterfeld, M. D., Müller-Trutwin, M. C., Margolis, D. M., Bar, K. J., Li, J. Z., McCune, J. M., Lewin, S. R., Kulpa, D. A., et al. (2024) · Pathogens and Immunity · doi:10.20411/pai.v8i2.696
Huang, S., Zhang, W., Katanski, C. D., Dersh, D., Dai, Q., Lolans, K., Yewdell, J. W., Eren, A. M., & Pan, T. (2021) · Figshare · doi:10.6084/m9.figshare.17132932
McCormick, C. A. (2024) · Digital Repository Service (Northeastern University) · doi:10.17760/d20659808
Jiang, X. R., Zhan, L., & Tang, X. (2024) · Cellular Signalling · doi:10.1016/j.cellsig.2024.111242
RetractedAugmenting the landscape of chimeric antigen receptor T-cell therapy
Srivastava, S., Singh, S. K., & Singh, A. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2372330
Eggert, T. W., & Kleiner, R. E. (2024) · Methods and principles in medicinal chemistry · doi:10.1002/9783527840458.ch12
mRNA Vaccine: The Starting Point of the Human Body Revolution
Jiang, W. (2024) · Highlights in Science Engineering and Technology · doi:10.54097/4edpd319
RNA Modifying Proteins: Emerging Targets for Drug Discovery
Boriack‐Sjodin, P. A., & Silver, S. J. (2024) · Royal Society of Chemistry eBooks · doi:10.1039/9781837674916-00500
Drug Discovery for Chromatin Readers, Writers, Erasers, Remodelers and Epitranscriptomic Targets
(2024) · Royal Society of Chemistry eBooks · doi:10.1039/9781837674916-part3
Ghoshal, B., Chakraborty, D., Nag, M., Varadarajan, R., & Jhunjhunwala, S. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.31.621287
Supotnitskiy, M. V. (2024) · Journal of NBC Protection Corps · doi:10.35825/2587-5728-2024-8-3-205-231
RNA as a Mediator of Host-Fungal Pathogenesis
Bruch, A., & Blango, M. G. (2024) · The mycota · doi:10.1007/978-3-031-64853-3_5
Immune Responses to mRNA Vaccine
Exposito, J., Monge, C., Arruda, D. C., & Verrier, B. (2024) · Wiley eBooks · doi:10.1002/9783527838394.ch2
Cancer Vaccines Based on mRNA: Hype or Hope?
de Mey, W., Autaers, D., Bertazzon, G., Esprit, A., Aragon, M. M., Franceschini, L., & Breckpot, K. (2024) · Wiley eBooks · doi:10.1002/9783527838394.ch13
Hong, F., Castro, M. M., & Linse, K. D. (2025) · Exploration of Digital Health Technologies · doi:10.37349/edht.2025.101142
Lea, M. J., Fonderson, C., Prabhakar, P. S., Pandya, B. U., Yee, K., Takyi, N. A., & Wetmore, S. D. (2025) · Canadian Journal of Chemistry · doi:10.1139/cjc-2024-0276
Bene, A. D., D’Aniello, A., Mottola, S., Mazzarella, V., Cutolo, R., Campagna, E., Benedetti, R., Altucci, L., Cosconati, S., Maro, S. D., et al. (2025) · RSC Medicinal Chemistry · doi:10.1039/d5md00032g
RNA modifications as a novel mediator of viral infection
Netzband, R. (2021) · doi:10.54014/2mrc-jsvn
Fundamental Biochemical Pathways and Processes in Cellular Physiology
Akers, R. M., & Denbow, D. M. (2025) · doi:10.1002/9781394304288.ch3
Structural biology and computer-aided drug design
Singh, P., Hassan, S., Mehdi, M. M., Kumar, V. R., & Biswas, K. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-27461-9.00008-1
Assessing the Immunogenicity of Synthetic RNA Using Blood Cells
Sioud, M. (2025) · Methods in molecular biology · doi:10.1007/978-1-0716-4742-4_6
Analysis of the mRNA modification machinery alterations in breast cancer through the SCAN-B cohort
Peula, C., Esteva-Socias, M., Kumari, K., Dassi, E., & Aguiló, F. (2025) · NAR Cancer · doi:10.1093/narcan/zcaf027
Yan, Z. (2025) · Cambridge University Press eBooks · doi:10.1017/9781009381338.012
Yan, Z. (2025) · Cambridge University Press eBooks · doi:10.1017/9781009381338.005
Choi, J., Jeong, T. U., Cabanting, F., Song, J., Park, C., Hwang, S., Kang, J. Y., Kang, J., Fang, L., & Jun, Y. W. (2025) · Angewandte Chemie · doi:10.1002/ange.202516389
Choi, J., Jeong, T. U., Cabanting, F., Song, J., Park, C., Hwang, S., Kang, J. Y., Kang, J., Fang, L., & Jun, Y. W. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202516389
Minimal Polymerase-Containing Precursor Required for Chikungunya Virus RNA Synthesis
Aponte-Diaz, D., Jain, A., Harris, J. M., Arnold, J. J., & Cameron, C. E. (2025) · Viruses · doi:10.3390/v17121556
Huang, S., Zhang, W., Katanski, C. D., Dersh, D., Dai, Q., Lolans, K., Yewdell, J., Eren, A. M., & Pan, T. (2021) · Figshare · doi:10.6084/m9.figshare.17132935
Huang, S., Zhang, W., Katanski, C. D., Dersh, D., Dai, Q., Lolans, K., Yewdell, J., Eren, A. M., & Pan, T. (2021) · Figshare · doi:10.6084/m9.figshare.17132929
Cantero, M. J., Bueloni, B., Gonzalez Llamazares, L., Fiore, E. J., Mauriz, L. L., Atorrasagasti, C., Mazzolini, G. D., Malvicini, M., Bayo, J., & García, M. G. (2024) · Figshare · doi:10.6084/m9.figshare.26264916
Lu, X., Xu, G., Lin, Z., Zou, F., Liu, S., Zhang, Y., Fu, W., Jiang, J., Ma, X., & Song, J. (2024) · Figshare · doi:10.6084/m9.figshare.26561851
Zhang, C., & Zhang, B. (2025) · Encyclopedia of Life Sciences · doi:10.1002/9780470015902.a0029844
Therapeutic potential of exogenous mRNA encoding recombinant antibodies against viral pathogens
Klotchenko, S. A., & Plotnikova, M. A. (2025) · Medical academic journal · doi:10.17816/maj642736
Kim, J., Moon, K., Kim, J., Park, S.-J., Kim, N., Jung, Y., Lee, Y., Lee, K., Yoo, W., Kim, J. H., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03109
Qin, W., Nie, T., Hei, M., Li, L., Pan, Y., Luo, M., & Yang, G. (2026) · Research · doi:10.34133/research.1172
mRNA-based COVID-19 vaccination and risk of autoimmune diseases in the pediatric population
Polavarapu, M., Singh, S., Mukundan, D., & Bova, E. (2026) · Annals of Epidemiology · doi:10.1016/j.annepidem.2026.110077
LNP-mRNA immunogenicity and toxicity
Thalla, M., Pasika, S. R., Bulusu, R., Reddy, D. S., Mundrathi, V., & Shukla, P. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-45006-8.00008-2
A Novel Immune-Modulating Nanodrug Enhances Liver-Targeted mRNA Delivery
Luo, D., Guo, D., Luo, M., Li, Y., Luo, J., & Lu, H. (2026) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c01715
Yuan, H., Zhang, B., Qiu, L., Han, J., Jia, L., Wang, X., Liu, Y., Li, H., Wen, H., & Li, L. (2026) · Microorganisms · doi:10.3390/microorganisms14040756
Imaging and safety profiling of inhaled siRNA RyR2 in human respiratory models
Bettinsoli, V., Erlacher, M., Galbiati, V., Marinovich, M., Corsini, E., & Wilflingseder, D. (2026) · Archives of Toxicology · doi:10.1007/s00204-026-04370-7
Enhancement of Therapeutic mRNA Translation in Cellular Stress Conditions
Trepkowska-Mejer, E. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27114663
Belhaouari, D. B., Pant, A., Navarro-Forero, S., Cantu, F., & Yang, Z. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2605194123
Xu, Y., Zhang, X.-B., & Zhang, J.-P. (2026) · Human Gene Therapy · doi:10.1177/10430342261454725
The impact of psuedouridine modification on human tRNA
Stone, Y., Morgan, E., Su, Y.-H., Kuo, C., & Lin, T. (2026) · Biochemical Society Transactions · doi:10.1042/bst20250258
Martin, A. L., Cotterell, J., Buick, K. H., Bird, T. W., Kuang, J., Palmer, O. R., Mason, N. C., White, L. G., Draper, S. L., Foster, A. J., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.11.731499
Draycheva, A., Millecam, J., & Caba, E. (2026) · International Journal of Toxicology · doi:10.1177/10915818261446630
D’Amico, C., Miska, M., Saarinen, S., Säkkinen, V., & Kostiainen, M. A. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.25.734245
Analytical Characterization and Stability Assessment of RNA-Based Vaccines
Alasmari, H., Alghannam, S. F., Almoammar, H., Alrabiah, D. K., Harthy, S. A., Alyamani, E. J., Alyahya, S. A., Alkhrayef, M. N., Fallatah, M., Al‐Khaldi, S., et al. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18070790
Current progress in developing mRNA-lipid nanoparticle vaccines against human bacterial pathogens
Pullinger, B., Harbison-Price, N., Sebina, I., Na, J., Belz, G. T., & Walker, M. J. (2026) · Clinical Microbiology Reviews · doi:10.1128/cmr.00138-26
Wanted and unwanted modifications of mRNA and their effect on gene expression and signaling
Urs, A. N. N., Dali, A., & Zaher, H. S. (2026) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2026.113314
Ma, Y., Deng, W., Jiang, X., & Zhu, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1857099
PUS7 mRNA pseudouridylation is driven by RNA sequence, structure, and cell-type-specific features
Rodell, R., Jain, R., Shenasa, H., Montes, M., Robalin, N., Prodic, S., Eyras, E., & Martínez, N. M. (2026) · Cell Genomics · doi:10.1016/j.xgen.2026.101332
Kojasoy, V., & Raines, R. T. (2026) · Physical Chemistry Chemical Physics · doi:10.1039/d6cp01428c
Miles, J. R., Masterson, S., Bellows, E., Fisher, F., Rani, R., Marelli, S., Hardman, C., Grassi, L., Santos, L., James, V. H., et al. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.103058
Guérin, M., Saorin, A., & Martinez‐Serra, A. (2026) · Health Nanotechnology · doi:10.1186/s44301-026-00036-6 · Cited by 2
Epitranscriptomic regulation of host–virus interactions
Mehra, S., Phadnis, S., Kumar, Y. S. R., Singh, A., & Verma, B. (2026) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2026.168423 · Cited by 1
Cold-adapted RNA polymerase from Pseudomonas phage Njord improves synthesis of therapeutic mRNA
Nye, D. B., Chen, T.-H., Curcuru, J. L., Wolf, E. J., Molé, C. N., Kunte, V. A., Ryan, M., Mitchell, L., Schwarz, D. S., Whipple, J. M., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2606667123
Recoding by N1-methylpseudouridine guides rational mRNA vaccine design
Poulis, P., Robecchi, G., Kurochkina, A., Felletti, M., & Rodnina, M. V. (2026) · Nature Communications · doi:10.1038/s41467-026-77796-3
RNabel─A Standalone Software Tool for Annotating Tandem Mass Spectra of Modified Ribonucleic Acids
Song, G., Du, Y.-J. N., Sun, R., & Dong, M. (2026) · Analytical Chemistry · doi:10.1021/acs.analchem.6c02176
Bioengineering strategies for improving the immunogenicity of mRNA vaccines
Wang, H., Zhuo, R., Wu, J., & Ouyang, S. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02991-z
Zhong, W., Sun, Q., Fang, L., Pratihar, S., Sanders, N. N., & Kool, E. T. (2026) · ACS Chemical Biology · doi:10.1021/acschembio.6c00657
Wang, Y., Ge, Y., Chen, Y., 杨永峰, & Li, J. (2026) · Journal of Hematology & Oncology · doi:10.1186/s13045-026-01857-9
Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)
Modjarrad, K., & Swanson, K. A. (2026) · Springer eBooks · doi:10.1007/978-3-032-37993-1_12
Programmable mRNA vaccine materials for temporal control of antitumour immunity
Jeong, S. D., Tang, C., Wang, X., Szeglowski, A., Kim, Y., Kim, B., Sharma, P., Moon, J. J., Jiang, W., & Kim, B. Y. S. (2026) · Nature Reviews Materials · doi:10.1038/s41578-026-00974-8
Mathematical modeling in mRNA therapeutics: towards a pathway to individualized treatment protocols
Campanile, E., Pettinà, E., & Marchetti, L. (2026) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2026.2744578
Metadata
- Authors
- Anderson, B. R., Muramatsu, H., Nallagatla, S. R., Bevilacqua, P. C., Sansing, L. H., Weissman, D., & Karikó, K.
- Affiliations
- Pennsylvania State University (US)
- Corresponding author
- Karikó, Katalin
- ORCID
- Venue
- Nucleic Acids Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-05-10
- Volume
- 38
- Issue
- 17
- Pages
- 5884-5892
- ISSN
- 0305-1048 (ISSN-L)
- 1362-4962
- PMC
- PMC2943593
- OpenAlex
- W2156788486
- Cited by
- 682
- References
- 60
- Citations by year
- 2026: 67 · 2025: 99 · 2024: 143 · 2023: 90 · 2022: 77 · 2021: 52 · 2020: 22 · 2019: 22 · 2018: 26 · 2017: 17 · 2016: 21 · 2015: 13 · 2014: 6 · 2013: 12 · 2012: 8
- FWCI
- 3.49
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Nucleic Acids Research (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- Cleveland Clinic
- Cleveland Clinic Foundation
- National Institutes of Health
- National Heart, Lung, and Blood Institute (R42HL087688)
- National Institute of General Medical Sciences (T32GM007229, R01GM058709)
- National Institute of Allergy and Infectious Diseases (R01AI050484)
- National Institute of Diabetes and Digestive and Kidney Diseases (T32DK007748)
- National Institute of Dental and Craniofacial Research (R21DE019059)
- National Center for Research Resources (T32RR007063)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA modifications and cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
- Keywords
- pseudouridine, mRNA translation, PKR, RNA-dependent protein kinase, eIF2α phosphorylation, translation initiation, uridine, in vitro transcribed mRNA, RNA-protein interactions
- MeSH terms
- Animals, Cell Line, Cells, Cultured, Humans, Pseudouridine, RNA, Messenger, Protein Biosynthesis, eIF-2 Kinase, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
